.svg){kind=small}
Risk mitigation is increasingly important in early medicines development not only to allow early attrition but also to improve the chances of early drug development.Join us at the 23rd AGAH Annual Meeting taking place 13-14 March 2014 in Munich, Germany. Discussions will take into account the impact of nonclinical findings, biopharmaceutics, personalised medicine approaches, updates on safety/tolerability from a clinical pharmacology perspective, as well as early investigation of lack of efficacy.View program and register online
-min.jpg)
.jpg)
Latest news
Futureproofing early phase clinical research for the next generation of investigators.
March 20, 2023
Richmond Pharmacology’s experienced Principal investigators and Co-investigators recently gave expert feedback on the ICH M11 (CeSHarP) protocol template.
Read moreDirector of Operations, Keith Berelowitz, has been appointed as the Research Ethics Committee Chair for the Health Research Authority.
January 19, 2023
Keith Berelowitz will be responsible for ensuring that all ethical possibilities are explored in relation to new research.
Read moreEvents
13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions
Sunday, June 4th to Tuesday June 6th 2023
Exchange research-based knowledge on drug-drug interactions (DDIs) among all interested stakeholders from pharmaceutical industry, regulatory authorities, academic and health care delivery backgrounds and perspectives.
View event
